CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
DCP-001biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04739527
NCT04739527Phase 1Completed
CompareCT.gov

An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

University Medical Center Groningen·interventional·Posted Feb 4, 2021·Updated May 1, 2026

In Brief

A Phase 1 clinical trial evaluating DCP-001 for Ovarian Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

Phase I study to evaluate safety and systemic immunogenicity of the DCP-001 vaccine in patients with high grade serous ovarian cancer after primary treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesNetherlands
CollaboratorsMendus

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedFeb 4, 2021
Enrollment StartJun 10, 2021
Primary CompletionDec 30, 2025
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 5.4 years ago

Interventions

DCP-001biological

allogeneic dendritic cell vaccine